Clinical Trial Update: Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation [Phase 2]

View source ↗

Summary

Phase 2 randomized study evaluating doxorubicin delivered by drug-eluting bead embolisation for hepatocellular carcinoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Doxorubicin (doxorubicin)

Snippet

Sponsor: Boston Scientific Corporation | Conditions: Primary Liver Cancer | Phase 2 | Status: COMPLETED